AXIM BIOTECHNOLOGIES, INC. (AXIM) Total liabilities 2015–2023
AXIM BIOTECHNOLOGIES, INC. (AXIM) total liabilities at each fiscal year-end, per SEC filings.
$11.8MFY2023 · since FY2015: $3.0M → $11.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | $11.8M | +15.4% |
| FY2022 | $10.2M | +33.2% |
| FY2021 | $7.7M | -21.4% |
| FY2020 | $9.7M | +15.3% |
| FY2019 | $8.5M | +3.4% |
| FY2018 | $8.2M | -3.6% |
| FY2017 | $8.5M | +121.9% |
| FY2016 | $3.8M | +29.2% |
| FY2015 | $3.0M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More AXIM financial trends
AXIM RevenueAXIM Net incomeAXIM Net marginAXIM Gross profitAXIM Gross marginAXIM Operating incomeAXIM Operating marginAXIM Operating cash flowAXIM Free cash flowAXIM Capital expendituresAXIM Return on equityAXIM Stock buybacksAXIM Dividends paidAXIM Total assetsAXIM Shareholders’ equityAXIM overview →